September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy: Results from the Pan-American Collaborative Retina Study Group (PACORES) at 24 Months of Follow-up
Author Affiliations & Notes
  • J Fernando Arevalo
    Retina Division, The Wilmer Eye Institute-Johns Hopkins University, Baltimore, Maryland, United States
  • Andres Lasave
    Retina and Vitreous Service, Clínica Privada de Ojos, Mar del Plata, Argentina
  • Lihteh Wu
    Instituto de Cirugia Ocular, San Jose, Costa Rica
  • Mauricio Maia
    Departamento de Oftalmologia - Instituto da Visão , Universidade Federal de São Paulo, São Paulo, Brazil
  • Manuel Diaz-Llopis
    Hospital Universitario, Valencia, Spain
  • Arturo Alezzandrini
    OFTALMOS, Universidad de Buenos Aires, Buenos Aires, Argentina
  • Miguel Brito
    Instituto Docente de Especialidades Oftalmológicas (IDEO), Maracaibo, Venezuela, Bolivarian Republic of
  • Footnotes
    Commercial Relationships   J Fernando Arevalo, None; Andres Lasave, None; Lihteh Wu, None; Mauricio Maia, None; Manuel Diaz-Llopis, None; Arturo Alezzandrini, None; Miguel Brito, None
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J Fernando Arevalo, Andres Lasave, Lihteh Wu, Mauricio Maia, Manuel Diaz-Llopis, Arturo Alezzandrini, Miguel Brito; Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy: Results from the Pan-American Collaborative Retina Study Group (PACORES) at 24 Months of Follow-up. Invest. Ophthalmol. Vis. Sci. 2016;57(12):No Pagination Specified.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To evaluate the effects of intravitreal bevacizumab (IVB) on retinal neovascularization (RN) in patients with proliferative diabetic retinopathy (PDR).

Methods : Retrospective multicenter interventional case series. Clinical records of 81 consecutive patients (97 eyes) with RN due to PDR who received at least one intravitreal injection of bevacizumab (IVB) were included. Patients examination included measurement of best-corrected Snellen visual acuity (BCVA), ophthalmoscopy, fluorescein angiography (FA), and optical coherence tomography (OCT) at baseline and follow-up visits.

Results : The mean age of patients was 55.6±11.6 years. The mean number of IVB injections per eye was 4±2.5 (range, 1 to 7 injections). The mean interval between IVB applications was 3.5±3.3 months. Sixty two (63.9%) eyes showed total regression of RN on fundus examination with absence of fluorescein leakage, 26 (26.8 %) eyes demonstrated partial regression of RN and 9 (9.3%) eyes had no regression. The mean duration of follow-up was 29.6±2 months (range, 24 to 30 months). BCVA and OCT improved statistically signficantly (p<0.0001, both comparisons). Three eyes without previous PRP ('naive' eyes) and with vitreous hemorrhage did not require vitreoretinal surgery. Five (5.2%) eyes with PDR progressed to tractional retinal detachment requiring vitrectomy, and 1 (1%) eye had vitreous hemorrhage with increased intraocular pressure (ghost cell glaucoma). No systemic adverse events were noted.

Conclusions : IVB resulted in marked regression of RN in patients with PDR and previous PRP. In a subgroup of eyes with no previous laser, only 42.1% achieved control or regression of PDR with IVB injections during 24 months of follow up without necessity of adjunctive laser or vitrectomy. There were no safety concerns over 2 years follow up of IVB for PDR.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.